Heart diseases in unani medicine

Effect of unani formulation on improvement of left ventricular diastolic dysfunction in patients of hypertension

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/04/018432

Enrollment

Registered

2019-04-05

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I998- Other disorder of circulatory system

Interventions

Intervention1: uani formulation (3.5 gm in capsules) along with Arq e gauzuban (35 ml ): 1. Badrooj (Ocimum basilicum L) 2. Sumbul-ut-tib (Dorema ammoniacum) 3. Darvanj aqrabi (Doronicum hookeri) 4.

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of diastolic dysfunction of grade 1st and 2nd

Exclusion criteria

Exclusion criteria: Diastolic dysfunction cases of grade 3rd and 4th patients with left ventricular ejection fraction less than 40% patients with a history of coronary artery bypass graft or stenting procedure known cases of valvular heart diseases and thyrotoxicosis pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
E/A (ratio of the early (E) to late (A) ventricular filling velocities IVRT (isovolumetric relaxation time) DT (deceleration time)Timepoint: Before and after intervention	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactMansoor Ahmad Suddiqui

National institute of unani medicine

mansoorsiddquidr@gmail.com9448124054

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026